Good question. Not sure. Perhaps so...there are many questions to be asked/answered/speculated on, such as:
Is RCPI pursuing Psoriasis and topical due to expediency to get approved, expediency to show demonstrative results, size of market potential, lower risk and higher reward for oral anatabine to be separate market focus...or perhaps due to non-safety side effects with their testing of oral version (or maybe in dosage variations)...all takes time. All of the above may be contributors. I suspect $ available to RCPI is a big factor in decision making. Seems like Roskamp grant for Gulf War System study may be avenue for FDA approval in US?
News 
Market Data 
Discover 
AI
